Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison
Nivolumab and cabozantinib, two new treatment options for previously-treated advanced/metastatic renal cell carcinoma (aRCC), have recently been approved.
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Camillo Porta, Cezary Szczylik, Roman Casciano, Shuai Fu, Billy Amzal, Johanna Lister, Helene Karcher, Jie Meng, Monika Neumann, Jerome Dinet Source Type: research